Join
Live feed
·
PRReleasevia Quantisnow
GT Biopharma Inc. logo

GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors

ByQuantisnow·Wall Street's wire, on your screen.
GTBP· GT Biopharma Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track GTBP (GT Biopharma Inc.) and more on Quantisnow.